Literature DB >> 14993667

Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3 beta.

Masaaki Aoki1, Takehiro Yokota, Ikuko Sugiura, Chizuko Sasaki, Tsukasa Hasegawa, Chieko Okumura, Koichi Ishiguro, Toshiyuki Kohno, Shigetoshi Sugio, Takao Matsuzaki.   

Abstract

Human tau-protein kinase I (TPK I; also known as glycogen synthase kinase 3 beta; GSK3 beta) is a serine/threonine protein kinase that participates in Alzheimer's disease. Here, binary complex structures of full-length TPK I/GSK3 beta with the ATP analogues ADP and AMPPNP solved by the X-ray diffraction method at 2.1 and 1.8 A resolution, respectively, are reported. TPK I/GSK3 beta is composed of three domains: an N-terminal domain consisting of a closed beta-barrel structure, a C-terminal domain containing a 'kinase fold' structure and a small extra-domain subsequent to the C-terminal domain. The catalytic site is between the two major domains and has an ATP-analogue molecule in its ATP-binding site. The adenine ring is buried in the hydrophobic pocket and interacts specifically with the main-chain atoms of the hinge loop. The overall structure and substrate-binding residues are similar to those observed in other Ser/Thr protein kinases, while Arg141 (which is not conserved among other Ser/Thr protein kinases) is one of the key residues for specific ATP/ADP recognition by TPK I/GSK3 beta. No residues are phosphorylated, while the orientation of the activation loop in TPK I/GSK3 beta is similar to that in phosphorylated CDK2 and ERK2, suggesting that TPK I/GSK3 beta falls into a conformation that enables it to be constitutively active.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14993667     DOI: 10.1107/S090744490302938X

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  10 in total

1.  A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity.

Authors:  Jessica L Buescher; Christopher J Phiel
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

2.  Fast and automated functional classification with MED-SuMo: an application on purine-binding proteins.

Authors:  Olivia Doppelt-Azeroual; François Delfaud; Fabrice Moriaud; Alexandre G de Brevern
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

3.  Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.

Authors:  Ki Hwan Kim; Irina Gaisina; Franck Gallier; Denise Holzle; Sylvie Y Blond; Andrew Mesecar; Alan P Kozikowski
Journal:  J Mol Model       Date:  2009-05-14       Impact factor: 1.810

4.  Perfluorooctanoic acid impaired glucose homeostasis through affecting adipose AKT pathway.

Authors:  Gang Du; Jinhong Sun; Yang Zhang
Journal:  Cytotechnology       Date:  2018-01-16       Impact factor: 2.058

5.  GSK-3β: A Bifunctional Role in Cell Death Pathways.

Authors:  Keith M Jacobs; Sandeep R Bhave; Daniel J Ferraro; Jerry J Jaboin; Dennis E Hallahan; Dinesh Thotala
Journal:  Int J Cell Biol       Date:  2012-05-21

6.  Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities study.

Authors:  Hongbo Xie; Haixia Wen; Denan Zhang; Lei Liu; Bo Liu; Qiuqi Liu; Qing Jin; Kehui Ke; Ming Hu; Xiujie Chen
Journal:  Oncotarget       Date:  2017-03-14

7.  High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer's disease using computational approaches.

Authors:  Rohit Shukla; Tiratha Raj Singh
Journal:  J Genet Eng Biotechnol       Date:  2021-05-04

8.  Structural insight into nucleotide recognition by human death-associated protein kinase.

Authors:  Laurie K McNamara; D Martin Watterson; Joseph S Brunzelle
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-02-20

9.  Preferential selectivity of inhibitors with human tau protein kinase gsk3β elucidates their potential roles for off-target Alzheimer's therapy.

Authors:  Jagadeesh Kumar Dasappa; H G Nagendra
Journal:  Int J Alzheimers Dis       Date:  2013-10-10

10.  Molecular features of product release for the PKA catalytic cycle.

Authors:  Adam C Bastidas; Jian Wu; Susan S Taylor
Journal:  Biochemistry       Date:  2014-08-08       Impact factor: 3.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.